

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Lexston Life Sciences Corp. (the “Company” or “Lexston”)
Suite 1150 – 789 W. Pender Street, Vancouver, BC V6C 1H2

Item 2. Date of Material Change

March 25, 2022

Item 3. News Release

The news release was sent for dissemination and filed on SEDAR and on the website of the Canadian Securities Exchange on March 25, 2022.

Item 4. Summary of Material Change

Mr. Dimitrios Mitrakos resigned as the Chief Financial Officer and Corporate Secretary of the Company. Company’s director Jatinder Jesse Manhas was appointed as the Chief Financial Officer and Corporate Secretary of the Company. Director Graeme Staley was appointed to the audit committee of the Company.

Item 5. Full Description of Material Change

Item 5.1 Full Description of Material Change

Mr. Dimitrios Mitrakos resigned as the Chief Financial Officer and Corporate Secretary of the Company. Company’s director Jatinder Jesse Manhas was appointed as the Chief Financial Officer and Corporate Secretary of the Company. Director Graeme Staley was appointed to the audit committee of the Company. The audit committee of the Company now consists of directors Jagdip Singh Bal, Harinder Bains and Graeme Staley.

Item 5.2 Disclosure for Restructuring Transactions

Not Applicable

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

The undersigned is aware of no information of a material nature that has been omitted.

Item 8. Executive Officer

Mr. Jag Bal, CEO & Director of the Company, is knowledgeable about the material change and this report. He can be contacted at (604) 928-8913.

Item 9. Date of Report

Dated March 25, 2022.